Catanionic lipid nanosystems improve pharmacokinetics and anti-lung cancer activity of curcumin

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 12, Issue 6, 2016, Pages 1567-1579

  Li, Songlin ^a   Fang, Chunshu ^a   Zhang, Jingqing ^b   Liu, Bilin ^b   Wei, Zhuanqin ^a   Fan, Xiaoqing ^a   Sui, Zheng ^a   Tan, Qunyou ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Anti lung cancer activity; Bioavailabilities; Catanionic lipid nanosystems; Curcumin; Signaling pathway

Indexed keywords

ANIONIC SURFACTANTS; BIOCHEMISTRY; BIOLOGICAL ORGANS; CATIONIC SURFACTANTS; CELL DEATH; CELL SIGNALING; DISEASES; DRUG PRODUCTS; PHARMACOKINETICS; TUMORS;

BIOAVAILABILITIES; CURCUMIN; LIPID NANOSYSTEMS; LUNG CANCER; SIGNALING PATHWAYS;

NANOSYSTEMS;

ANIONIC SURFACTANT; BIM PROTEIN; CURCUMIN; LIPID NANOCARRIER; MESSENGER RNA; NANOCARRIER; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOX1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; LIPID; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CANCER INHIBITION; CELL CYCLE S PHASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; IC50; IN VITRO STUDY; IN VIVO STUDY; LEWIS LUNG CARCINOMA CELL; LUNG CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; METASTASIS INHIBITION; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; DRUG EFFECTS; HUMAN; LUNG NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CURCUMIN; HUMANS; LIPIDS; LUNG NEOPLASMS; MICE; NANOPARTICLES; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION;

EID: 84965032322     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2016.02.007     Document Type: Article

References (59)

1. Komuro M., Kaneko M., Narukawa M. Investigation of prognostic factors affecting efficacy in carboplatin- and paclitaxel-based first-line chemotherapies for advanced non-small-cell lung cancer. Tumori 2015, 101:424-432.
2. Mehta H.J., Patel V., Sadikot R.T. Curcumin and lung cancer-a review. Target Oncol 2014, 9:295-310.
3. Tan Q., Li Y., Wu J., Mei H., Zhao C., Zhang J. An optimized molecular inclusion complex of diferuloylmethane: enhanced physical properties and biological activity. Int J Nanomedicine 2012, 7:5285-5393.
4. Xu X., Chen D., Ye B., Zhong F., Chen G. curcumin induces the apoptosis of non-small cell lung cancer cells through a calcium signaling pathway. Int J Mol Med 2015, 35:1610-1616.
5. Zhang J., Du Y., Wu C., Ren X., Ti X., Shi J., et al. Curcumin promotes apoptosis in human lung adenocarcinoma cells through miR-186* signaling pathway. Oncol Rep 2010, 24:1217-1223.
6. Ye M., Zhang J., Zhang J., Miao Q., Yao L., Zhang J. Curcumin promotes apoptosis by activating the p53-miR-192-5p/215-XIAP pathway in non-small cell lung cancer. Cancer Lett 2015, 357:196-205.
7. Tan Q., Wu J., Li Y., Mei H., Zhao C., Zhang J. A supermolecular curcumin for enhanced antiproliferative and proapoptotic activities: molecular characteristics, computer modeling and in vivo pharmacokinetics. Nanotechnology 2013, 24:035102.
8. Zhou Q.M., Wang X.F., Liu X.J., Zhang H., Lu Y.Y., Huang S., et al. Curcumin improves MMC-based chemotherapy by simultaneously sensitising cancer cells to MMC and reducing MMC-associated side-effects. Eur J Cancer 2011, 47:2240-2247.
9. Chen P., Li J., Jiang H.G., Lan T., Chen Y.C. Curcumin reverses cisplatin resistance in cisplatin-resistant lung cancer cells by inhibiting FA/BRCA pathway. Tumour Biol 2015, 36:3591-3599.
10. Charron D.M., Chen J., Zheng G. Theranostic lipid nanoparticles for cancer medicine. Cancer Treat Res 2015, 166:103-127.
11. Tan Q.Y., Zhang J., Wang N., Li X., Xiong H., Teng Y., et al. Uricase from Bacillus fastidious loaded in alkaline enzymosomes: Enhanced biochemical and pharmacological characteristics in hypouricaemic rats. Eur J Pharm Biopharm 2012, 82:43-48.
12. Hu J., Sun L., Zhao D., Zhang L., Ye M., Tan Q., et al. Supermolecular evodiamine loaded water-in-oil nanoemulsions: Enhanced physicochemical and biological characteristics. Eur J Pharm Biopharm 2014, 88:556-564.
13. Hu J., Chen D., Jiang R., Tan Q., Zhu B., Zhang J. Improved absorption and in vivo kinetic characteristics of nanoemulsions containing evodiamine-phospholipid nanocomplex. Int J Nanomedicine 2014, 9:4411-4420.
14. Wang W., Zhu R., Xie Q., Li A., Xiao Y., Li K., et al. Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles. Int J Nanomedicine 2012, 7:3667-3677.
15. Kuo Y.C., Liang C.T. Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor. Biomaterials 2011, 32:3340-3350.
16. Zhao G., Huang J., Xue K., Si L., Li G. Enhanced intestinal absorption of etoposide by self-microemulsifying drug delivery systems: roles of P-glycoprotein and cytochrome P450 3A inhibition. Eur J Pharm Sci 2013, 50:429-439.
17. Mauroy C., Castagnos P., Orio J., Blache M.C., Rico-Lattes I., Teissié J., et al. Versatile cellular uptake mediated by catanionic vesicles: simultaneous spontaneous membrane fusion and endocytosis. Mol Pharm 2015, 12:103-110.
18. Zhang J., Liu J., Li X.L., Jasti B.R. Preparation and characterization of solid lipid nanoparticles containing silibinin. Drug Deliv 2007, 14:381-387.
19. Zhong M., Feng Y., Liao H., Hu X., Wan S., Zhu B., et al. Azithromycin cationic non-lecithoid nano/microparticles improve bioavailability and targeting efficiency. Pharm Res 2014, 31:2857-2867.
20. Tan Q., Liu S., Chen X., Wu M., Wang H., Yin H., et al. Design and evaluation of a novel evodiamine-phospholipid complex for improved oral bioavailability. AAPS PharmSciTech 2012, 13:534-547.
21. Tan Q., Hu N., Liu G., Yin H.F., Zhang L., Wang H., et al. Role of a novel pyridostigmine bromide-phospholipid nanocomplex in improving oral bioavailability. Arch Pharm Res 2012, 35:499-508.
22. Lopes R.M., Gaspar M.M., Pereira J., Eleutério C.V., Carvalheiro M., Almeida A.J., et al. Liposomes versus lipid nanoparticles: comparative study of lipid-based systems as oryzalin carriers for the treatment of leishmaniasis. J Biomed Nanotechnol 2014, 10:3647-3657.
23. Parhi P., Sahoo S.K. Trastuzumab guided nanotheranostics: A lipid based multifunctional nanoformulation for targeted drug delivery and imaging in breast cancer therapy. J Colloid Interface Sci 2015, 451:198-211.
24. Oda Y., Suzuki R., Mori T., Takahashi H., Natsugari H., Omata D., et al. Development of fluorous lipid-based nanobubbles for efficiently containing perfluoropropane. Int J Pharm 2015, 487:64-71.
25. Wang J., Wang H., Zhu R., Liu Q., Fei J., Wang S. Anti-inflammatory activity of curcumin-loaded solid lipid nanoparticles in IL-1β transgenic mice subjected to the lipopolysaccharide-induced sepsis. Biomaterials 2015, 53:475-483.
26. Palange A.L., Di Mascolo D., Carallo C., Gnasso A., Decuzzi P. Lipid-polymer nanoparticles encapsulating curcumin for modulating the vascular deposition of breast cancer cells. Nanomedicine 2014, 10:991-1002.
27. Aditya N.P., Shim M., Lee I., Lee Y., Im M.H., Ko S. Curcumin and genistein coloaded nanostructured lipid carriers: in vitro digestion and antiprostate cancer activity. J Agric Food Chem 2013, 61:1878-1883.
28. Zhao X., Chen Q., Liu W., Li Y., Tang H., Liu X., et al. Codelivery of doxorubicin and curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver cancer. Int J Nanomedicine 2014, 10:257-270.
29. Danafar H., Davaran S., Rostamizadeh K., Valizadeh H., Hamidi M. Biodegradable m-PEG/PCL core-shell micelles: preparation and characterization as a sustained release formulation for curcumin. Adv Pharm Bull 2014, 4:501-510.
30. Gajra B., Dalwadi C., Patel R. Formulation and optimization of itraconazole polymeric lipid hybrid nanoparticles (Lipomer) using box behnken design. Daru 2015, 23:3-123.
31. Wang F., Chen L., Jiang S., He J., Zhang X., Peng J., et al. Optimization of methazolamide-loaded solid lipid nanoparticles for ophthalmic delivery using Box-Behnken design. J Liposome Res 2014, 24:171-181.
32. Kaur P., Garg T., Rath G., Murthy R.S., Goyal A.K. Development, optimization and evaluation of surfactant-based pulmonary nanolipid carrier system of paclitaxel for the management of drug resistance lung cancer using Box-Behnken design. Drug Deliv 2015, 10.3109/10717544.2014.993486.
33. Allam A.N., Komeil I.A., Fouda M.A., Abdallah O.Y. Preparation, characterization and in vivo evaluation of curcumin self-nano phospholipid dispersion as an approach to enhance oral bioavailability. Int J Pharm 2015, 489:117-123.
34. Ramalingam P., Ko Y.T. Enhanced oral delivery of curcumin from N-trimethyl chitosan surface-modified solid lipid nanoparticles: pharmacokinetic and brain distribution evaluations. Pharm Res 2015, 32:389-402.
35. Teixeira C.C., Mendonça L.M., Bergamaschi M.M., Queiroz R.H., Souza G.E., Antunes L.M., et al. Microparticles containing curcumin solid dispersion: stability, bioavailability and anti-Inflammatory activity. AAPS PharmSciTech 2015, 10.1208/s12249-015-0337-6.
36. Grill A.E., Koniar B., Panyam J. Co-delivery of natural metabolic inhibitors in a self-microemulsifying drug delivery system for improved oral bioavailability of curcumin. Drug Deliv Transl Res 2014, 4:344-352.
37. Jeengar M.K., Shrivastava S., Nair K., Singareddy S.R., Putcha U.K., Talluri M.V., et al. Improvement of bioavailability and anti-inflammatory potential of curcumin in combination with emu oil. Inflammation 2014, 37:2139-2155.
38. Memvanga P.B., Coco R., Préat V. An oral malaria therapy: curcumin-loaded lipid-based drug delivery systems combined with β-arteether. J Control Release 2013, 172:904-913.
39. Guri A., Gülseren I., Corredig M. Utilization of solid lipid nanoparticles for enhanced delivery of curcumin in cocultures of HT29-MTX and Caco-2 cells. Food Funct 2013, 4:1410-1419.
40. Cho Y.A., Lee W., Choi J.S. Effects of curcumin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen, in rats: possible role of CYP3A4 and P-glycoprotein inhibition by curcumin. Pharmazie 2012, 67:124-130.
41. Jia S., Xie P., Hong S.J., Galiano R., Singer A., Clark R.A., et al. Intravenous curcumin efficacy on healing and scar formation in rabbit ear wounds under nonischemic, ischemic, and ischemia-reperfusion conditions. Wound Repair Regen 2014, 22:730-739.
42. Chiu S.S., Lui E., Majeed M., Vishwanatha J.K., Ranjan A.P., Maitra A., et al. Differential distribution of intravenous curcumin formulations in the rat brain. Anticancer Res 2011, 31:907-911.
43. Sun J., Bi C., Chan H.M., Sun S., Zhang Q., Zheng Y. Curcumin-loaded solid lipid nanoparticles have prolonged in vitro antitumour activity, cellular uptake and improved in vivo bioavailability. Colloids Surf B: Biointerfaces 2013, 111:367-375.
44. Tripodo G., Pasut G., Trapani A., Mero A., Lasorsa F.M., Chlapanidas T., et al. Inulin-D-α-tocopherol succinate (INVITE) nanomicelles as a platform for effective intravenous administration of curcumin. Biomacromolecules 2015, 16:550-557.
45. Yoon I.S., Park J.H., Kang H.J., Choe J.H., Goh M.S., Kim D.D., et al. Poly(d, l-lactic acid)-glycerol-based nanoparticles for curcumin delivery. Int J Pharm 2015, 488:70-77.
46. Helson L., Bolger G., Majeed M., Vcelar B., Pucaj K., Matabudul D. Infusion pharmacokinetics of Lipocurc™ (liposomal curcumin) and its metabolite tetrahydrocurcumin in Beagle dogs. Anticancer Res 2012, 32:4365-4370.
47. Wei X., Senanayake T.H., Bohling A., Vinogradov S.V. Targeted nanogel conjugate for improved stability and cellular permeability of curcumin: synthesis, pharmacokinetics, and tumor growth inhibition. Mol Pharm 2014, 11:3112-3122.
48. Li X., Chen T., Xu L., Zhang Z., Li L., Chen H. Preparation of curcumin micelles and the in vitro and in vivo evaluation for cancer therapy. J Biomed Nanotechnol 2014, 10:1458-1468.
49. Bansal S.S., Kausar H., Vadhanam M.V., Ravoori S., Pan J., Rai S.N., et al. Curcumin implants, not curcumin diet, inhibit estrogen-induced mammary carcinogenesis in ACI rats. Cancer Prev Res (Phila) 2014, 7:456-465.
50. Berginc K., Suljaković S., Škalko-Basnet N., Kristl A. Mucoadhesive liposomes as new formulation for vaginal delivery of curcumin. Eur J Pharm Biopharm 2014, 87:40-46.
51. Ji H.F., Shen L. Can improving bioavailability improve the bioactivity of curcumin?. Trends Pharmacol Sci 2014, 35:265-266.
52. Sridhar R., Ravanan S., Venugopal J.R., Sundarrajan S., Pliszka D., Sivasubramanian S., et al. Curcumin- and natural extract-loaded nanofibres for potential treatment of lung and breast cancer: in vitro efficacy evaluation. J Biomater Sci Polym Ed 2014, 25:985-998.
53. Boztas A.O., Karakuzu O., Galante G., Ugur Z., Kocabas F., Altuntas C.Z., et al. Synergistic interaction of paclitaxel and curcumin with cyclodextrin polymer complexation in human cancer cells. Mol Pharm 2013, 10:2676-2683.
54. Liu H., Liu Y.Z., Zhang F., Wang H.S., Zhang G., Zhou B.H., et al. Identification of potential pathways involved in the induction of cell cycle arrest and apoptosis by a new 4-arylidene curcumin analogue T63 in lung cancer cells: a comparative proteomic analysis. Mol Biosyst 2014, 10:1320-1331.
55. Yang C.L., Liu Y.Y., Ma Y.G., Xue Y.X., Liu D.G., Ren Y., et al. Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through Janus kinase-STAT3 signalling pathway. PLoS One 2012, 7:e37960.
56. Gargini R., Cerliani J.P., Escoll M., Antón I.M., Wandosell F. Cancer stem cell-like phenotype and survival are coordinately regulated by Akt/FoxO/Bim pathway. Stem Cells 2015, 33:646-660.
57. Lu Y., Wei C., Xi Z. Curcumin suppresses proliferation and invasion in non-small cell lung cancer by modulation of MTA1-mediated Wnt/β-catenin pathway. In Vitro Cell Dev Biol Anim 2014, 50:840-850.
58. Chen Q.Y., Zheng Y., Jiao D.M., Chen F.Y., Hu H.Z., Wu Y.Q., et al. Curcumin inhibits lung cancer cell migration and invasion through Rac1-dependent signaling pathway. J Nutr Biochem 2014, 25:177-185.
59. Vallianou N.G., Evangelopoulos A., Schizas N., Kazazis C. Potential anticancer properties and mechanisms of action of curcumin. Anticancer Res 2015, 35:645-651.